Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine Gemcitabine has mild systemic toxicity. Only a few cases of severe pulmonary damage, especially evident as acute respiratory distress syndrome (ARDS) which is the extreme manifestation of a process defined as acute lung injury (ALI) [1], have been described, but following several months of therapy [2] [3] [4] . A 70-year-old man, with no previous medical history, was admitted for abdominal pain and weight loss. Diagnostic procedures disclosed pancreatic adenocarcinoma with liver metastasis. Gemcitabine was prescribed according to the usual schedule as a palliative therapy. Six days after its first administration clinical evaluation revealed tachypnea, pulmonary crackles, cardiac arrhythmia and arterial hypoxemia (PaO 2 / FiC>2 255 torr). We observed bilateral interstitial infiltration on chest X-ray and an electrocardiogram demonstrated atrial fibrillation with high ventricular response. Restoration of the sinus rhythm, without significant improvement in gas exchange, was noted 18 hours after administration of digoxin, furosemide and oxygen (FiC>2 33%). Myocardial damage markers were constantly negative and pulmonary perfusion scintigram excluded acute embolism.
Gemcitabine has mild systemic toxicity. Only a few cases of severe pulmonary damage, especially evident as acute respiratory distress syndrome (ARDS) which is the extreme manifestation of a process defined as acute lung injury (ALI) [1] , have been described, but following several months of therapy [2] [3] [4] . A 70-year-old man, with no previous medical history, was admitted for abdominal pain and weight loss. Diagnostic procedures disclosed pancreatic adenocarcinoma with liver metastasis. Gemcitabine was prescribed according to the usual schedule as a palliative therapy. Six days after its first administration clinical evaluation revealed tachypnea, pulmonary crackles, cardiac arrhythmia and arterial hypoxemia (PaO 2 / FiC>2 255 torr). We observed bilateral interstitial infiltration on chest X-ray and an electrocardiogram demonstrated atrial fibrillation with high ventricular response. Restoration of the sinus rhythm, without significant improvement in gas exchange, was noted 18 hours after administration of digoxin, furosemide and oxygen (FiC>2 33%). Myocardial damage markers were constantly negative and pulmonary perfusion scintigram excluded acute embolism.
We performed an echocardiogram and a radionuclide angiocardiogram which showed normal left ventricular function. A diagnosis of ALI was made and a high-dose corticosteroid therapy plus an increase in oxygen concentration (FiC>2 50%) by non-invasive mechanical ventilation were carried out. Pulmonary damage was completely reversed at clinical and radiologic assessment (PaO 2 /FiO2 400 torr) 12 days after its onset.
The pathogenetic mechanism of ALI is an inflammatory reaction of the alveolar-capillary wall, cytokine-mediated, which creates an abnormal permeability of its membrane. This results in an accumulation of fluid and inflammatory cells in the interstitial spaces. Evaluation of the alveolar-capillary clearance (ACC) using the 99m Tc-diethylen triamine pentacetic acid (DTPA) lung ventilatory scintigram may quantify, in vivo, the wall damage [5] . The patient inhaled 750 MBq of DTPA via an aerosol delivery unit that generates particles with a mean diameter of 1.1 microns. Forty frames of 30 seconds each were taken over the lung and the degree of wall damage is presented as the clearance rate (%/min) calculated from the time-activity curve and corrected for tracer decay (k). The ACC rate observed four days after the onset of symptoms was 1.4% ±0.5%/min. On the same day, transoesophageal atrial stimulation (TAS) by bursts of 400 pulses per minute (ppm) induced sustained atrial fibrillation, spontaneously reverting within eight hours. At discharge the patient was prescribed methylprednisolone (50 mg/day) [6] but no antiarrhythmic drug. After two weeks of corticosteroid therapy, DTPA ventilatory scintigram and TAS were repeated. We observed a decrease of the alveolar-capillary clearance (0,78% ±0.15%/ min), signifying an improvement in the wall damage resulting from endothelial cell regeneration. The electrophysiological study showed unsustained atrial fibrillation induced only after an aggressive protocol of stimulation (bursts of 600 ppm) lasting a few seconds, at that time clinically insignificant. Gemcitabine provokes pulmonary damage by an inflammatory mechanism, resulting in myofibroblast proliferation and collagen deposits [2] . Atrial fibrillation may be due to the same pathogenetic mechanism. Our hypothesis is supported by the observation of Frustaci, who detected inflammatory infiltrates in atrial biopsies of patients suffering from atrial fibrillation with no cardiovascular disease [7] . These patients, despite antiarrhythmic drugs, benefited from corticosteroid treatment for arrhythmia control. After informed consent, gemcitabine plus methylprednisolone (50 mg/day) were administrated with no apparent side effects. The reduction of inflammatory response with prolonged corticosteroid therapy may explain the absence of cardio-pulmonary damage despite persistent chemical insult. Seven months later, after initial clinical improvement, malignant disease proceeded. Atrial fibrillation recurred and the results of both the echocardiogram and the radionuclide angiocardiogram were again insignificant. The patient died, showing clinical signs of multiple organ failure. Permission was not granted to perform an autopsy.
Our observations lead us to believe that a suitable antiinflammatory therapy could be used to prevent pulmonary and/or cardiac side effects. This could be useful in the treatment of symptomatic patients affected by a cancer which responds to gemcitabine. 
